KSPH.F Stock Overview
Researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Kissei Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥23.26 |
| 52 Week High | JP¥25.00 |
| 52 Week Low | JP¥19.32 |
| Beta | -0.043 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 18.37% |
| 5 Year Change | -16.93% |
| Change since IPO | 15.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| KSPH.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.3% | 2.4% | -0.8% |
| 1Y | n/a | 4.3% | 22.7% |
Return vs Industry: Insufficient data to determine how KSPH.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how KSPH.F performed against the US Market.
Price Volatility
| KSPH.F volatility | |
|---|---|
| KSPH.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: KSPH.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine KSPH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 1,779 | Mutsuo Kanzawa | www.kissei.co.jp |
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Kalogra tablets, for the treatment of ulcerative colitis; Tabuneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Malizeb tablets; Tavaris tablets for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. Its products in pipeline include CG0070, which is in Phase III clinical trial to treat non-muscle-invasive bladder cancer; Linzagolix, which is in Phase III clinical trial for the treatment of uterine fibroids and endometriosis; KDT-3594, which is in Phase II clinical trial to treat Parkinson's disease; KSP-0243 that is in Phase II clinical trial to treat Ulcerative colitis; and Difelikefalin, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients.
Kissei Pharmaceutical Co., Ltd. Fundamentals Summary
| KSPH.F fundamental statistics | |
|---|---|
| Market cap | US$1.09b |
| Earnings (TTM) | US$69.19m |
| Revenue (TTM) | US$522.73m |
15.8x
P/E Ratio2.1x
P/S RatioIs KSPH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KSPH.F income statement (TTM) | |
|---|---|
| Revenue | JP¥81.07b |
| Cost of Revenue | JP¥40.63b |
| Gross Profit | JP¥40.44b |
| Other Expenses | JP¥29.71b |
| Earnings | JP¥10.73b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 03, 2025
| Earnings per share (EPS) | 250.69 |
| Gross Margin | 49.88% |
| Net Profit Margin | 13.24% |
| Debt/Equity Ratio | 0.6% |
How did KSPH.F perform over the long term?
See historical performance and comparisonDividends
2.3%
Current Dividend Yield36%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 19:47 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kissei Pharmaceutical Co., Ltd. is covered by 17 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ritsuo Watanabe | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Global Markets Japan Inc. |
| Hidemaru Yamaguchi | Citigroup Inc |